Third Quarter 2022 Financial Results Conference Call
For Fiscal Year Ending Jun 30, 2021
Stay informed and receive updates directly to your inbox.Sign up today
iBio, Inc. (NYSE MKT: IBIO), is a global leader in plant-based biologics manufacturing. Its FastPharming System® combines automated hydroponics, vertical farming and glycan engineering technologies to increase speed-to-clinic of scalable, consistently high-quality monoclonal antibodies, antigens, bioinks and other recombinant proteins. iBio is leveraging its FastPharming Technologies to develop novel biopharmaceuticals for respiratory and fibrotic disease indications, among others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s FastGlycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins.